Document Detail


Acadesine extends the window of protection afforded by ischaemic preconditioning.
MedLine Citation:
PMID:  8174159     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim was to test whether acadesine (5-amino-4-imidazolecarboxamide riboside, AICAR), an adenosine regulating agent which increases tissue adenosine during ischaemia, could prolong the window of protection from ischaemic preconditioning. METHODS: A branch of the left coronary artery of a rabbit heart was occluded for 30 min and reperfused for 180 min to induce infarction. Infarct size was determined with triphenyl tetrazolium staining. Prior to the 30 min ischaemia, rabbits were subjected to one of the following seven protocols: (1) No treatment (controls). (2) Preconditioning with 5 min of regional ischaemia followed by 2 h of reperfusion. (3) Treatment with acadesine (2.5 mg.kg-1.min-1 intravenously for 5 min starting 155 min prior to 30 min ischaemia followed by 210 min infusion of 0.5 mg.kg-1.min-1. (4) Treatment with acadesine (same schedule as in group 3) plus preconditioning as in group 2. (5) Treatment with acadesine for a shorter period (acadesine 2.5 mg.kg-1.min-1 for 5 min starting 30 min prior to preconditioning followed by 0.5 mg.kg-1.min-1 for only 60 min) plus preconditioning as in group 2. (6) Treatment with preconditioning followed by adenosine receptor blockade with 8-(p-sulphophenyl)theophylline (SPT) 10 mg.kg-1 intravenously immediately after and again 15 min after preconditioning. (7) Treatment with short infusion of acadesine plus preconditioning plus SPT. RESULTS: Preconditioning followed by 2 h of reperfusion offered little protection against infarction [28.6(SEM 2.7)% of the ischaemic zone infarcted] as compared to control [38.7(3.1)% infarction]. Treatment with acadesine alone did not modify the infarct size [37.8(3.5)%], but both of the acadesine plus preconditioning groups showed a significant limitation of infarct size with 13.9(3.1)% infarction in group 4 and 12.7(2.2)% infarction in group 5 (both p < 0.01 v control). Although SPT alone did not modify the infarct size [26.8(3.3)%], SPT blocked the protective effect of acadesine [25.3(2.9)%, p < 0.05 v group 5]. CONCLUSION: Acadesine can delay the natural decay of preconditioning. This delay appeared to be mediated by adenosine and may have therapeutic potential.
Authors:
A Tsuchida; X M Yang; B Burckhartt; K M Mullane; M V Cohen; J M Downey
Related Documents :
20118409 - Role of the gap junction in ischemic preconditioning in the heart.
11560359 - Dilazep dihydrochloride prolongs the infarct size-limiting effect of ischemic precondit...
8071859 - Role of bradykinin in myocardial preconditioning.
20098279 - Sildenafil citrate augments myocardial protection in heart transplantation.
11294809 - Gene therapy with extracellular superoxide dismutase protects conscious rabbits against...
10860759 - Cardioprotective effects of 17 beta-estradiol produced by activation ofmitochondrial at...
3212769 - Assessment of hypertrophy in myocardial biopsies taken during correction of congenital ...
17306709 - Impact of patient-prosthesis mismatch and aortic valve design on coronary flow reserve ...
7826309 - Myocardial perfusion measured by dual-isotope acquisition of 81rubidium/81mkrypton: an ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cardiovascular research     Volume:  28     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  1994 Mar 
Date Detail:
Created Date:  1994-06-08     Completed Date:  1994-06-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  379-83     Citation Subset:  IM    
Affiliation:
University of South Alabama, College of Medicine, Mobile 36688.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine / metabolism
Aminoimidazole Carboxamide / analogs & derivatives*,  pharmacology
Animals
Female
Male
Myocardial Infarction / pathology,  prevention & control*
Myocardial Ischemia / metabolism*
Myocardial Reperfusion
Myocardium / metabolism,  pathology
Rabbits
Ribonucleosides / pharmacology*
Theophylline / analogs & derivatives,  pharmacology
Time Factors
Chemical
Reg. No./Substance:
0/Ribonucleosides; 2627-69-2/acadesine; 360-97-4/Aminoimidazole Carboxamide; 58-55-9/Theophylline; 58-61-7/Adenosine; 80206-91-3/8-(4-sulfophenyl)theophylline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Release of calcium from guinea pig cardiac sarcoplasmic reticulum induced by sodium-calcium exchange...
Next Document:  Recovery of attenuated baroreflex sensitivity in conscious dogs after reversal of pacing induced hea...